Targeted therapies in the treatment of non small cell lung cancer: Reality and hopes

Current Opinion in Oncology

Volumn 16, Issue 2, 2004, Pages 126-129

  Gridelli, Cesare ^a  

^a S G MOSCATI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 PROPYL 3 [3 [2 ETHYL 4 (4 FLUOROPHENYL) 5 HYDROXYPHENOXY]PROPOXY]PHENOXY]BENZOIC ACID; AE 941; ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; CANERTINIB; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETORICOXIB; GEFITINIB; ISIS 2503; ISIS 3521; LONAFARNIB; OBLIMERSEN; PACLITAXEL; PRINOMASTAT; PROTEIN TYROSINE KINASE INHIBITOR; REBIMASTAT; ROFECOXIB; SEMAXANIB; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB; VANDETANIB; VASCULOTROPIN RECEPTOR; ZD 2171;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EDITORIAL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN FAMILY; QUALITY OF LIFE; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; EICOSANOIDS; HUMANS; LUNG NEOPLASMS; QUALITY OF LIFE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 1642447062     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200403000-00007     Document Type: Editorial

References (15)

1. Parkin DM, Bray F, Ferlay J, et al.: Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94:153-156.
2. Gridelli C, Rossi A, Maione P: Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Oncogene 2003, 22:6629-6638.
3. Korn EL, Arbuck SG, Pluda JM, et al.: Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol 2001, 19:265-272.
4. Ciardiello F, Tortora G: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001, 7:2958-2970.
5. Gridelli C, Maione P, Castaldo V, et al.: Gefitinib in elderly and unfit patients affected by advanced non-small cell lung cancer. Br J Cancer 2003, 89:1827-1829.
6. Giaccone G, Johnson DH, Manegold C, et al.: A phase III clinical trial of ZD1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (INTACT 1). Ann Oncol 2002, 13:2.
7. Johnson DH, Herbst R, Giaccone G, et al.: ZD1839 (Iressa) in combination with paclitaxel & carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Ann Oncol 2002, 13:127.
8. Fukuoka M, Yano S, Giaccone G, et al.: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003, 21:2237-2246.
9. Kris MG, Natale BR, Herbst RS, et al.: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290:2149-2158.
10. Langer CJ, Adak S, Thor A, et al.: Phase II Eastern Cooperative Oncology Group (ECOG) pilot study of paclitaxel (P), carboplatin (C), and trastuzumab (T) in HER-2/neu (+) advanced non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 2001, 20:315a.
11. Gatzemeier U, Groth G, Hirsch V, et al.: Gemcitabine/cisplatin alone and with trastuzumab (Herceptin) in patients with non-small cell lung cancer overexpressing HER2: results of a randomised phase II study [abstract]. Proc Am Soc Clin Oncol 2002, 21:297a.
12. Johnson DH, DeVore R, Kabbinavar F, et al.: Carboplatin (C) + paclitaxel (T) + rhuMAb-VEGF (AVF) may prolong survival in advanced non-squamous lung cancer [abstract]. Proc Am Soc Clin Oncol 2001, 20:315a.
13. Yuen A, Halsey J, Fisher G, et al.: Phase I/II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 2001, 20:309a.
14. Gridelli C, Maione P, Airoma G, et al.: Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer. Curr Med Chem 2002, 9:1851-1858.
15. Gridelli C: How to combine cytotoxic and cytostatic agents. Lung Cancer 2002, 38:S39-S40.